Drug Trial Radar · NCT05624554
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 16, 2023
Primary completion
May 19, 2027
Study completion Mar 17, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
NemtabrutinibDrug
65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
FludarabineDrug
25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
CyclophosphamideDrug
250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
BendamustineDrug
Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
RituximabBiological
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
TruximaBiological
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
RuxienceBiological
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
RiabniBiological
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 49 months
Locations
97 sites in 21 countries. Site status is shown where the registry gives one.
Highlands Oncology Group ( Site 5205)
Springdale, Arkansas
Clermont Oncology Center ( Site 5224)
Clermont, Florida
Hattiesburg Clinic Hematology/Oncology ( Site 5216)
Hattiesburg, Mississippi
Medical Oncology Associates, PS ( Site 5206)
Spokane, Washington
Royal Adelaide Hospital ( Site 1105)
Adelaide, South Australia, Australia
Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1319)
Rio de Janeiro, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)
São Paulo, Brazil
Hospital Paulistano-Americas Oncologia ( Site 1302)
São Paulo, Brazil
Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1317)
Curitiba, Paraná, Brazil
Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304)
Jaú, São Paulo, Brazil
A. C. Camargo Cancer Center ( Site 1318)
São Paulo, São Paulo, Brazil
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD ( Site 6404)
Plovdiv, Bulgaria
Medical Centre Pratia Clinic EOOD ( Site 6406)
Plovdiv, Bulgaria
UMHAT "Prof. Dr. Stoyan Kirkovich"AD-Clinical Hematology ( Site 6400)
Stara Zagora, Bulgaria
Multriprofile Hospital for Active Treatment "Hristo Botev" ( Site 6402)
Vratsa, Bulgaria
Specialized Hospital for Active Treatment of Haematology Diseases ( Site 6403)
Sofia, Sofia (stolitsa), Bulgaria
James Lind Centro de Investigacion del Cancer ( Site 1503)
Temuco, Araucania, Chile
Biocenter ( Site 1507)
Concepción, Biobio, Chile
IC La Serena Research ( Site 1506)
La Serena, Coquimbo Region, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509)
Santiago, Region M. de Santiago, Chile
FALP-UIDO ( Site 1500)
Santiago, Region M. de Santiago, Chile
Clínica Inmunocel ( Site 1511)
Santiago, Region M. de Santiago, Chile
Peking University Third Hospital ( Site 1602)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital ( Site 1605)
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Hospital ( Site 1609)
Chongqing, Chongqing Municipality, China
Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 1607)
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center ( Site 1608)
Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University ( Site 1625)
Guiyang, Guizhou, China
Hainan General Hospital ( Site 1603)
Haikou, Hainan, China
Henan Cancer Hospital-hematology department ( Site 1613)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 1619)
Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1618)
Wuhan, Hubei, China
Xiangya Hospital Central South University-Hematology department ( Site 1616)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 1615)
Changsha, Hunan, China
The First Affiliated Hospital of Soochow University-hematology department ( Site 1612)
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University ( Site 1614)
Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital ( Site 1628)
Nanchang, Jiangxi, China
The First Hospital of Jilin University-Hematology ( Site 1621)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 1617)
Xi'an, Shaanxi, China
Shaanxi provincial people's hospital ( Site 1626)
Xi'an, Shaanxi, China
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.